Peer-reviewed veterinary case report
Immune and blood vessel markers in dogs on metronomic chemo for cancer
By Denies, S et al.·Published in Veterinary and comparative oncology·2017·Department of Nutrition·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients.
- Species:
- dog
Plain-English summary
A group of dogs with cancer underwent treatment with metronomic chemotherapy using temozolomide and cyclophosphamide to see how it affected their immune system and blood vessel growth. Blood tests showed that the treatment reduced certain immune cells (regulatory T cells) in some dogs, which could help boost their immune response against cancer. However, the levels of specific proteins related to blood vessel growth did not change significantly with the treatments. While the study provided insights into the immune response, it did not report on the overall effectiveness of the treatments in improving the dogs' health or survival.
People also search for: dog cancer treatment options · metronomic chemotherapy for dogs · temozolomide side effects in dogs
Abstract
Metronomic chemotherapy stimulates the immune response via depletion of regulatory T cells (Tregs) and suppresses angiogenesis by modulating the secretion of thrombospondin-1 (TSP-1) and vascular endothelial growth factor (VEGF). In this study, blood was collected from 10 healthy dogs and from 30 canine cancer patients before and 2 and 4 weeks after treatment with metronomic temozolomide (6.6 mg m), cyclophosphamide (12.5 mg m) or cyclophosphamide and temozolomide. The percentage of circulating CD25Foxp3CD4Tregs and the plasma levels of TSP-1 and VEGF were measured. There was a significant difference in the percentage of Tregs between cancer patients and healthy dogs. A significant decrease in Tregs was noted in patients treated with metronomic cyclophosphamide and the combination. Treatment with temozolomide had no effect on the percentage of Tregs. TSP-1 and VEGF levels were, respectively, significantly lower and higher in cancer patients than in healthy dogs, but they were not influenced by any of the studied metronomic treatment regimens.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26961119/